Link to Full Report Well-funded and on track Brighton, United Kingdom – 9 April 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance (AMR), announces its audited financial results for the year ended 31 December 2018. Financial […]
Link to full article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma appoints MedPharm to develop new XF‐platform drug formulations MedPharm will develop potential XF‐platform formulations as treatments for dermal and ocular infections Brighton, United Kingdom ‐ 27th March 2019 ‐ Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]
Link to full article THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or […]
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Second positive […]
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma […]
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform. Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: […]
Brighton, United Kingdom – 1 November 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has been jointly awarded a National Biofilms Innovation Centre (NBIC) funded research collaboration with the University of Southampton. The […]
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Directorate Change […]
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report Brighton, United Kingdom – 24 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address […]
Destiny Pharma plc (“Destiny Pharma” or the “Company”) A series of videos and explainer documents launched, focusing on cutting-edge R&D taking place in UK biotech companies, including Destiny Pharma Destiny Pharma has been chosen to exemplify the UK’s leading status in antimicrobial resistance research Brighton, United Kingdom – 19 October 2018 – Destiny Pharma (AIM: DEST), […]